Is Cardio Risk Check | Herz-Kreislauf Risiko-Test useful for Wechseljahre?

Based on the provided context, there is no direct information about a 'Cardio Risk Check' or 'Herz-Kreislauf Risiko-Test' specifically for menopause. Generally, cardiovascular risk increases after menopause due to declining estrogen. Established clinical risk scores (e.g., SCORE2, Framingham) are validated for this period and recommended by guidelines. A consumer test that includes genetic markers (like MTHFR, ALDH2, FTO) or microbiome analysis may offer additional insights, but the evidence for its added value in menopause is limited. Many genetic associations come from GWAS and lack clinical actionability. Polygenic risk scores are less reliable for non-European populations. Therefore, such a test might be used as a supplementary tool, but it should not replace standard medical risk assessment. Caveat: Do not make health decisions based solely on a consumer test; consult a physician for interpretation and follow-up.